Genetic alterations in Rb2/p130 gene have been reported in several tumors, but till now there are insufficient and conflicting data linking the loss of pRb2/p130 expression with the mutational status of this gene in lung cancer. We recently reported that loss or lowering of pRb2/p130 expression is mainly due to aberrant Rb2/p130 promoter methylation, in retinoblastoma tumors, and indicated that epigenetic silencing of Rb2/p130 can impair its function to negatively regulate cell cycle progression as well as apoptotic response. In order to clarify Rb2/p130 gene inactivation in lung cancer, we investigated whether epigenetic events could impair the expression of this gene in NSLC. Here, we show that specific Rb2-exon 1 homozygous mutations, occurring in an Rb2/p130, region, rich in CpG dinucleotides, could be the 'hit event' that predispose this gene to epigenetic changes, leading to Rb2/p130 gene silencing in lung cancer. Moreover, these homozygous mutations, found in different tumor histotypes, could represent tumor-specific markers.
Introduction
Although the importance of genetic alterations in cancer has been long recognized, the role of epigenetic changes in affecting tumor formation and progression has been suggested only recently (Macaluso and Giordano, 2004; Scarano et al., 2005) . Epigenetic events are mediated by DNA methylation and chromatin remodeling via histone acetylation, methylation and phosphorylation, which lead to the formation of transcriptionally repressive chromatin states resulting in gene silencing (La Sala et al., 2003; Macaluso et al., 2003a, b; Nephew and Huang, 2003) . These mechanisms affect the transcription of key genes involved in the regulation of cellular growth, differentiation, apoptosis, transformation and tumor progression (Macaluso and Giordano, 2004; Macaluso et al., 2005a) . Recent studies have suggested that aberrant methylation may be an early event inactivating cancer-related genes in lung tumors (Zochbauer-Muller et al., 2002; Belinsky, 2004; Suzuki et al., 2005) . In addition, multiple genetic alterations, including the activation of oncogenes as well as loss and/ or inactivation of tumor suppressor genes, have been described in lung cancers (Yokota and Kohno, 2004) . In this context, pRb2/p130 retinoblastoma-related protein is emerging to play a role in lung tumorigenesis, even if the mechanisms leading to aberrant pRb2/p130 expression in these tumors are not yet clearly elucidated (Baldi et al., 1997; Claudio et al., 2000) .
Genetic alterations in Rb2/p130 gene have been reported in different tumors, but till now there is insufficient data to link the loss of pRb2/p130 expression with the mutational status of this gene. Our study and other studies already reported mutations of Rb2/ p130 in non-small lung cancer (NSLC) and small-lung cancer (SCLC) cells, even if these mutations partially justify the absence of the pRb2/p130 protein (Helin et al., 1997; Claudio et al., 2000) . We recently reported that loss or lowering of pRb2/p130 expression is mainly due to aberrant Rb2/p130 promoter methylation in retinoblastoma tumors (Tosi et al., 2005) . Therefore, in order to clarify the role of Rb2/p130 gene inactivation in lung carcinogenesis, we begin to investigate whether epigenetic events impair the expression of this gene in NSLC.
Here, we show that specific Rb2-exon 1 homozygous mutations, occurring in an Rb2/p130 -region, rich in CpG dinucleotides, could be the 'hit event' that predisposes it to epigenetic changes leading to Rb2/p130 gene silencing in lung cancer. In addition, since we found these homozygous mutations in different tumor histotypes, we suggest that these mutations could represent tumor-specific markers. Moreover, we discuss the possibility that the re-expression of endogenous Rb2/p130 gene, epigenetically silenced, could provide a mean to suppress tumor growth in lung cancer.
Results

Specific homozygous mutations could impair Rb2/p130 expression
To check if the low expression levels of both pRb2/p130 mRNA and protein in non-small lung carcinoma H23 cell line (Figure 1a and b) is due to genetic alterations occurring in Rb2/p130 gene, we screened H23 DNA for mutations in Rb2/p130 coding regions by using properly designed primers able to amplify each of the 22 exons. The obtained sequences have been matched with the wild-type sequences derived from placenta DNA (Access numbers X74594 and X76061) present in Gene Bank (Li et al., 1993; Mayol et al., 1993) . No mutations were found from exons 2 to 22, while two exon 1 homozygous mutations at nucleotides 178 and 259 were found in H23 cells (Figure 1c -e). Exon 1 mutations were no more evident when matching was done with the Rb2/ p130 genome sequence labeled in Gene Bank as S67171 (Hannon et al., 1993) . Interestingly, this latter Gene Bank sequence derives from HeLa-S3 cell line, a human cervix epithelia carcinoma. To check whether these mutation are associated with a tumoral phenotype, we screened the nucleotide sequence of Rb2/p130 exon 1 in different cancer cell lines and primary tumors. T-limphoblastoid leukemia (CCRF-CEM, Molt-1 and Jurkat), B-limphoblastoid leukemia (Daudi), chronic myeloid leukemia (K562), breast carcinoma (SK-Br3 and MCF-7), retinoblastoma (Weri-Rb1) and colon cancer (HT29) cell lines, as well as retinoblastoma, ovarian, colon and endometrial primary tumors have been analysed. In all these samples, we detected exon 1 homozygous/heterozygous mutations at nucleotides 178 and 259. Interestingly, the same two mutations were present in the normal-appearing endometrial tissue (as confirmed by histology) derived from the same patients taken in the adjacent nontumoral area as far as possible from the tumor site. In addition, none mutations were detected in normal retina, lung, ovary, endometrius, breast and colon tissues from patients affected by nontumoral pathologies and in 15 healthy donors blood samples (data not shown). Therefore, we hypothesize that exon 1 homozygous mutations could represent tumor-specific markers since they have not been detected in normal tissues and healthy donor samples.
Mutations found at nucleotide 178 (TCT-CCT) and 259 (CCC-GCC) of the exon 1 determined the substitution of serine to proline (codon 37) and proline to alanine (codon 64), respectively, (Figure 1d and e). However, only the change at codon 37 (serine to proline) lead to the substitution of amino acid with different biochemical characteristics since a neutral polar amino acid was replaced with a neutral nonpolar amino acid. Therefore, there is the possibility that this serine-proline substitution may lead to protein conformation change impairing the pRb2/p130 stability. However, on the other hand, these missense mutations occurring in the exon 1 region, rich in CpG dinucleotides, could be the 'hit event' that predispose Rb2/p130 gene to epigenetic 
Rb2/p130 silencing by epigenetic events
We assess the methylation status of Rb2/p130 gene focusing our analysis on regions rich in CpG dinucleotide: the promoter region immediately 5 0 -flaking to the transcription start site (ATG), the exon 1 and the intron 1 (Figure 3a) . By performing methylation-specific PCR (MSP) assay, we identified the methylation of Rb2/ p130-specific regions, the regions M1 (À95 bp to þ 177 bp) and M3 ( þ 287 bp to þ 411 bp) in H23 cells (Figure 3b and c) . Moreover, we tested the effect of DNA methyltransferase inhibitor (5-Aza-2-deoxycytidine) on the Rb2/p130-mRNA expression and we also assessed whether the 5-Aza-dC treatment was sufficient to restore the expression of endogenous pRb2/p130 in H23 cell lines. The effects of the demethylating agent on both Rb2/p130 mRNA and -protein expression level at different times from the 5-Aza-dC treatment are shown in Figure 4a and b. By using multiplex RT-PCR, we observed an increase of Rb2/p130 mRNA level, beginning at 48 h after the 5-Aza-dC-treatment (Figure 4a ). Moreover, we also observed an increase of pRb2/p130 protein levels, in its active hypophosphorylated form, at 72 h from the 5-Aza-dC treatment reaching a maximum at 96 h (Figure 4b ).
Discussion
Taken together, our data strongly support the hypothesis that epigenetic events can occur to downregulate Rb2/p130 transcription in NSLC H23 cells. We believe that Rb2/p130 aberrant methylation could be triggered by the homozygous nucleotide substitutions occurring in exon 1 of the gene. These mutations may locally alter the chromatin structure and create the necessary environment to recruit specific chromatin-modifying enzymes that can work to deny the access of basal transcription complex on the Rb2/p130 gene. As we previously demonstrated, aberrant methylation of Rb2/p130 gene can lead to a loss or lowering of pRb2/p130 expression in tumor cells, thus impairing its tumor-suppressor functions to negatively regulate cell cycle progression as well as apoptotic response ( 
Genetic alterations
Figure 2 Tumorigenesis may spring from the combined forces of both genetic and epigenetic events. Mutations at nucleotide 178 (TCT-CCT) and 259 (CCC-GCC) of the exon 1 determine the substitution of serine to proline (codon 37) and proline to alanine (codon 64), respectively. (a) These amino-acid substitutions may lead to protein conformation change impairing the pRb2/p130 stability; (b) on the other hand, these missense mutations occurring in the exon 1 region, rich in CpG dinucleotides, could be the 'hit event' that predispose Rb2/p130 gene to epigenetic changes leading to silencing of gene and tumor promotion
Epigenetic silencing of Rb2/p130 gene in lung cancer C Caterina et al Macaluso et al., 2003a, b; Tosi et al., 2005) . Accumulating evidence indicates that CpG island hypermethylation in the promoter regions of regulatory genes is an early event in cancer development and may precede the neoplastic process (Nephew and Huang, 2003 Modi et al., 2000; Xue Jun et al., 2003) . Here, we show that lung carcinogenesis may spring from the combined forces of both genetic and epigenetic events altering cancer susceptibility genes. We believe that aberrant methylation of the cytosine base within the regulatory area of Rb2/p130 gene could be a common event in different cancers, and could contribute to the molecular pathogenesis of lung tumors through inactivation of pRb2/p130-regulated pathways. Our hypothesis is supported by several studies indicating that pRb2/p130 play a key role in controlling the expression and the function of both cell cycle and apoptosis-related genes (La Sala et al., 2003; Macaluso et al., 2003a, b; Russo et al., 2003) . Moreover, our study and other studies have indicated that either mutations and/or aberrant methylation could impair pRb2/p130 tumor suppressor function, in different tumor histotypes (Helin et al., 1997; Cinti et al., 2000; Tosi et al., 2005) .
Since hypermethylation is an important hallmark in clinical oncology, ongoing trials are evaluating the safety and efficacy of agents affecting epigenetic changes in cancer patients (Kalebic, 2003; Macaluso et al., 2003a Macaluso et al., , b, 2005b . The knowledge gained about the role of the genetic and epigenetic modifications impairing Rb2/p130 gene stimulate new attractive therapeutic approach offering a target for the treatment and/or prevention of lung cancer.
Materials and methods
Cell cultures and treatment
Cell lines were purchased from the American Type Culture Collection (Rockinville, MD). The cells were cultured in Epigenetic silencing of Rb2/p130 gene in lung cancer C Caterina et al DMEM or RPMI1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine. For treatment, cells were seeded at a density of 5 Â 10 5 cells/100-mm tissue culture dish. In total, 2.5 mM of DNA methyltransferase inhibitor (5-Aza-2-deoxicytidine) was added to the culture medium for up to 96 h.
Analysis of Rb2/p130 mRNA and protein expression level in H23 cells
Total RNA from the human NSLC (H23) cell line was extracted using TRIzol (Life Technologies) according to the manufacturer's protocol. The RNA was electrophoresed in a formaldehyde (Sigma) agarose gel (Kodak), transferred overnight to a Hybond N þ Nylon membrane (Amersham) and the filter was UV crosslinked. The membrane was hybridized with a random primer-labeled cDNA probe (Rb2/p130 fragment), washed and exposed to a Kodak X-ray film at À801C. The levels of Rb2/p130 mRNA were normalized with the level of GAPDH mRNA.
Western blotting analysis of pRb2/p130 was performed using total protein lysates from untreated and 5-Aza-2-deoxicytidine treated H23 cells. Whole-cell lysates were prepared in lysis buffer (50 mM Tris/HCl, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton-X, 0.1 mM Na 3 VO 4 plus fresh inhibitors). Equal amounts of 100 mg of total extracts were loaded and resolved on a 7% SDS-PAGE. The gels were then transferred onto a nitrocellulose filter and checked by using 0.1% Ponceau red. The monoclonal antipRb2/p130 (Transduction Laboratories, KY, USA) was used at a dilution of 1 : 800.
Rb2/p130 mutational analysis and MSP assay
High molecular weight genomic DNA from H23 cells was isolated using the Qiamp Tissue Kit (Qiagen, Valencia, CA, USA) following the manufacturer's suggested protocol. PCR of genomic DNA was used to perform mutational analysis of Rb2/p130. All 22 exons were amplified and sequenced as previously described (Tosi et al., 2005) .
The methylation status of Rb2/p130 was evaluated using MSP assay (CpGenome, Intergene, NY, USA). The regions analysed were 5 0 -flanking to the transcription started site (ATG), the exon 1 and intron 1. Primers were specifically designed to discriminate between methylated (Tm ¼ 661C), unmethylated (Tm ¼ 611C) and wild-type DNA (Tm ¼ 681C) (Figure 3a and b) . PCR products were analysed on 2.5% agarose gel.
Multiplex RT-PCR
Multiplex RT-PCR analysis was carried out using 0.2 mg of total RNA from treated and untreated H23 cells. PCR was performed using Rb2/p130-and b-actin-specific primers (SuperScript RT-PCR System, Invitrogen).
